Complimentary DNA (cDNA) News and Research

RSS

Reversible cell-specific drug delivery with aptamer-functionalized liposomes

For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug also must spare healthy cells, and ideally its effects will be reversible to cut short any potentially dangerous side effects. Investigators from the University of Illinois at Urbana-Champaign report that they have assembled a new cancer drug delivery system that, in cell culture, achieves all of the above.

7 Sep 2009

OriGene Technologies releases recombinant proteins purified from HEK293 cells

OriGene Technologies, Inc. announces the release of 5,000 purified human proteins, representing the most comprehensive offering of human cell-produced human proteins.

25 Aug 2009

Scientists challenge current views on how genes are controlled in mammals

Scientists at the Omics Science Center (OSC) of the RIKEN Yokohama Institute in Japan - along with researchers from McGill University and other institutions worldwide - are challenging current notions of how genes are controlled in mammals.

22 Apr 2009

Discovery of master switch that might prevent cancer cells from metastasizing

Researchers at the University of Pennsylvania School of Medicine have identified a master switch that might prevent cancer cells from metastasizing from a primary tumor to other organs.

16 Mar 2009

Biologically tagged nanowires integrated onto circuit chips

A handheld, ultra-portable device that can recognize and immediately report on a wide variety of environmental or medical compounds may eventually be possible, using a method that incorporates a mixture of biologically tagged nanowires onto integrated circuit chips, according to Penn State researchers.

19 Jan 2009

Genomics in China

Ten years ago, the Chinese National Human Genome Center at Shanghai (South Center, hereafter) was established in the Zhangjiang HiTech Park of Pudong District in Shanghai.

7 Jan 2009

Invitrogen launches patent licensing program for random prime amplification of nucleic acids

Invitrogen Corporation today announced that it has signed non-exclusive agreements with New England Biolabs, Inc., QIAGEN GmbH, and Kirkegaard & Perry Laboratories, Inc. (KPL), whereby the companies have licensed Invitrogen's patented technology covering the random prime amplification of nucleic acids. Financial terms of the agreements were not disclosed.

4 Sep 2008

Most comprehensive kinome collection

Scientists from University of Helsinki, Institute of Molecular Medicine in Finland and OriGene Technologies joined effort in creating the most comprehensive kinome collection of nearly all predicted human protein kinases, including the functional kinases and their kinase-deficient counterparts. Equipped with this collection, the authors successfully identified novel kinase regulators in Hedgehog signaling pathway and in activation of Karposi's Sarcoma herpesvirus.

5 May 2008

Cancer treatment from a common avian virus under study

Researchers on the Blacksburg and College Park, Maryland campuses of the Virginia-Maryland Regional College of Veterinary Medicine have been awarded a major new grant from the National Institutes of Health (NIH) to support innovative work that seeks to develop a treatment for cancer from a common avian virus.

7 Apr 2008

Case Western Reserve researchers breed a "Lance Armstrong" mouse

Case Western Reserve University researchers have bred a line of "mighty mice" (PEPCK-Cmus mice) that have the capability of running five to six kilometers at a speed of 20 meters per minute on a treadmill for up to six hours before stopping.

2 Nov 2007

Brain function is even more impaired in cirrhotic than non-cirrhotic alcoholics

Sustained exposure to alcohol can cause scarring and dysfunction of the liver, referred to as cirrhosis.

28 Aug 2007

New tumor antigen found with new cloning technique

In recent years, researchers have worked to develop a number of vaccines to help the immune system fight tumors.

16 Apr 2007

Ryogen licenses gene patent to Invitrogen

Ryogen LLC announced today that the company have entered into a nonexclusive license agreement with Invitrogen Corporation, whereby Invitrogen has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.

9 Jan 2007

Ryogen licenses gene patent to OriGene Technologies

Ryogen and OriGene Technologies have announced today that they have entered into a nonexclusive license agreement whereby OriGene has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.

15 Aug 2006

Ryogen licenses human aminopeptidase P gene patent

Ryogen and R&D Systems have announced that they have entered into a nonexclusive license agreement whereby RDSI has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.

10 Jul 2006

Combination of genetic mutation and viral infection may cause prostate cancer

Significant recent interest in the literature (JAMA 2006;295:1503, Lancet, epub) and by patients has arisen in response to a presentation given by Dr. Eric Klein of the Cleveland Clinic at the 2006 Prostate Cancer Symposium in San Francisco, February 24, 2006.

3 May 2006

Cells have a natural defense against HIV

Scientists here have discovered a previously unknown mechanism that cells use to fight off the human immunodeficiency virus (HIV), the cause of AIDS.

14 Mar 2006

First identification of the genetic basis of disease in a patient with a complex I assembly defect

Mitochondrial complex I deficiency is one of the most common defects in patients with mitochondrial disease. The deficiency results from a failure to assemble the enzyme properly, but the nature of the molecular chaperones that are necessary for this process in mammals have remained obscure.

3 Oct 2005

Neurologix announces positive interim results of gene therapy clinical trial for patients with Parkinson's disease

Neurologix has announced positive interim results of its landmark gene therapy clinical trial for patients with Parkinson's disease. Neurologix's 12-patient, dose-escalating Phase I trial is the world's first study to use a viral vector (the non-pathogenic adeno-associated virus, or AAV) for the treatment of an adult neurological disease.

26 Sep 2005

New clues about the location of genes potentially involved in the most common type of lung cancer

Using technology that makes it possible to zoom in on smaller sections of cell chromosomes than ever before, researchers at Dana-Farber Cancer Institute have identified nearly 100 chromosome regions where genes are either over-copied or missing in non-small cell lung cancer.

27 Jun 2005